Table 2.

RSV immunoprophylaxis by target populations. Monoclonal antibodies are categorised into sequences of clinical phases (I, II, III) for two different population groups: paediatric and adults.

Population	Phase I	Phase II	Phase III	Market Approved
Children	-	-	Clesrovimab (MK-1654) fully human mAb (IgG1) binding RSV F protein site IV, half-life: 73–88 days, single injection	Palivizumab Humanized mAb (IgG1) binding RSV F protein site II, half-life: 20 days, monthly intramuscular injection
	TNM001 human anti-RSV mAb injection	-	-	Nirsevimab fully human mAb (IgG1) binding RSV F protein site Ø, YTE mutation of the Fc, half-life: 65–70 days, single intramuscular injection
Adults	RSM01 Humanized mAb (IgG1) binding RSV F protein site Ø, half-life: 65–70 days, single injection	-	-	-

Abbreviations: IgG1—immunoglobulin G subclass 1; mAb—monoclonal antibody; RSV—respiratory syncytial virus.